Identification

Name
Difluocortolone
Accession Number
DB09095
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submited to the FDA in July 1984 by the pharmaceutical company Schering AG.[3]

Structure
Thumb
Synonyms
  • Diflucortolone
Product Ingredients
IngredientUNIICASInChI Key
Difluocortolone pivalateZR05N7827615845-96-2UWGRWFCLGQWKPR-GSTUPEFVSA-N
Difluocortolone valerate1A63Z067C859198-70-8HHJIUUAMYGBVSD-YTFFSALGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nerisone CreamCream0.1 %TopicalGlaxosmithkline Inc1983-12-312016-07-12Canada
Nerisone Oily CreamCream0.1 %TopicalGlaxosmithkline Inc1983-12-312016-09-30Canada
Nerisone OintmentOintment0.1 %TopicalGlaxosmithkline Inc1983-12-312015-11-03Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Nerisalic Oily CreamDifluocortolone valerate (0.1 %) + Salicylic acid (3.0 %)CreamTopicalGlaxosmithkline Inc1995-12-312012-02-21Canada
Categories
UNII
K253365DXI
CAS number
2607-06-9
Weight
Average: 394.459
Monoisotopic: 394.195565708
Chemical Formula
C22H28F2O4
InChI Key
OGPWIDANBSLJPC-RFPWEZLHSA-N
InChI
InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14S,15S,17S)-1,8-difluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

Difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis. All these disorders present as a common characteristic the occurrence of symptoms as itching, swelling, redness and scaling.[4]

Structured Indications
Not Available
Pharmacodynamics

Diflucortolone is a steroid with the properties of being an anti-inflammatory, antipruritic and vasoconstrictive.[1] Its activity causes the vasoconstriction of the blood vessels and thus a decrease in the release of inflammatory substances. These actions produce the effect of skin soothed and elimination of the symptoms.[4]

Mechanism of action

Diflucortolone performs its action by the induction of lipocortins which are phospholipase A2 inhibitory proteins and sequentially inhibiting the release of arachidonic acid. The absence of arachidonic acid translates to the inhibition of the formation, release and activity of endogenous chemical inflammatory mediators. Another mechanism of action is the transrepression in which diflucortolone binds to the glucocorticoid receptor which induces its migration to the nucleus where it stimulates the transcription of anti-inflammatory genes like tyrosine aminotransferase, phophoenolpyruvate carboxykinase, IL-10, etc. and suppress the expression of proinflammatory genes like cytokines, growth factors, adhesion molecules, etc.[1]

TargetActionsOrganism
AAnnexin A3
inducer
Human
AGlucocorticoid receptor
binder
Human
Absorption

The absorption of diflucortolone is made mainly percutaneously but it may be absorbed systemically. The absorption and bioavailability of diflucortolone will be related to the type of formulation found in the medication.[1] The percutaneous absorption depends on the vehicle, dose, treatment area, duration of treatment, the condition of treatment, the status of penetration barrier and localization of treated area in the body.[6] Thus, rectal administration of diflucortolone produces a slow and low absorption with an AUC, Cmax and Tmax of 10.8 ng h/ml, 0.75 ng/ml and 4.7 h, respectively.[5]

Volume of distribution

Less of 1% of the administered dose reaches systemic circulation.[7] In order to exert its functions, diflucortolone has to distribute into the living epidermis and upper dermis. Reports have shown that the skin absorption of diflucortolone is rapid where the absorption gets significantly increased in damaged skin. Diflucortolone gets percutaneously absorbed and distributed into organs and tissues where it will be metabolized. When diflucortolone in an ointment form is applied in healthy skin 0.7% of the administered dose is percutaneously absorbed after a 7-hour exposure.[6]

Protein binding

Diflucortolone gets rapidly metabolized and eliminated, thus there is a very limited circulation of the unchanged drug in blood plasma.[6] Actually, the percutaneous absorption is so low that less than 1% of the admministered dose reaches systemyc circulation.[7]

Metabolism

The metabolism of diflucortolone is done in the liver where it is very rapidly degraded. After 5 minutes of administration of diflucortolone in a dose of 1mg, there is a concentration of intact diflucortolone in plasma of 6-8 ng/ml. The analysis of the metabolites showed the presence of 11-keto-diflucortolone as the major metabolite in the plasma.[2]

Route of elimination

The elimination of diflucortolone is rapid and complete. After 24 hours of dose administration 56% of the dose was eliminated by the urine and after 7 days 98% of the administered dose was recovered. The excretion of diflucortolone is subdivided in urine which accounts for 75% of the administered dose and in feces that accounts for the other 25% of the administered dose. From the eliminated dose, 30% was formed by unconjugated steroids, 20% as steroid-glucuronides and 10% as steroid-sulfates.[2]

Half life

The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[2]

Clearance

Diflucortolone gets rapidly eliminated and the metabolites produced are the latest in getting eliminated from the body.[6]

Toxicity

Diflucortolone can cause skin irritation, vesicles or red patches on the skin.[4]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Difluocortolone.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Difluocortolone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Difluocortolone.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Difluocortolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Difluocortolone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Difluocortolone.Approved, Withdrawn
AldesleukinDifluocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Difluocortolone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Difluocortolone.Experimental
AloglutamolThe bioavailability of Difluocortolone can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Difluocortolone.Experimental
AluminiumThe bioavailability of Difluocortolone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Difluocortolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Difluocortolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Difluocortolone.Approved
AmiodaroneThe serum concentration of Difluocortolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BDifluocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Difluocortolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Difluocortolone.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Difluocortolone.Approved, Investigational
ApalutamideThe serum concentration of Difluocortolone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Difluocortolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Difluocortolone.Approved, Investigational
AprepitantThe serum concentration of Difluocortolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Difluocortolone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Difluocortolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Difluocortolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Difluocortolone.Approved
AzosemideDifluocortolone may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Difluocortolone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Difluocortolone.Experimental
BendroflumethiazideDifluocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Difluocortolone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Difluocortolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Difluocortolone.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Difluocortolone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Difluocortolone.Experimental
Bismuth SubcitrateThe bioavailability of Difluocortolone can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Difluocortolone can be decreased when combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Difluocortolone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Difluocortolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Difluocortolone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Difluocortolone.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Difluocortolone.Experimental
BumetanideDifluocortolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluocortolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Difluocortolone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Difluocortolone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideDifluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Difluocortolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Difluocortolone.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Difluocortolone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difluocortolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Difluocortolone.Approved, Investigational
CeritinibDifluocortolone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Difluocortolone.Approved, Investigational, Vet Approved
ChlorothiazideDifluocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Difluocortolone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneDifluocortolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difluocortolone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Difluocortolone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Difluocortolone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Difluocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Difluocortolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Difluocortolone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Difluocortolone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Difluocortolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Difluocortolone.Approved, Investigational
CyclopenthiazideDifluocortolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Difluocortolone can be increased when it is combined with Daidzein.Experimental
DanazolDifluocortolone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Difluocortolone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Difluocortolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Difluocortolone.Approved, Vet Approved
DienestrolThe serum concentration of Difluocortolone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Difluocortolone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Difluocortolone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluocortolone.Approved, Investigational
DistigmineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Difluocortolone.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Difluocortolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Difluocortolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Difluocortolone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Difluocortolone.Approved
EpitizideDifluocortolone may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Difluocortolone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Difluocortolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Difluocortolone can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Difluocortolone can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Difluocortolone can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Difluocortolone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Difluocortolone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Difluocortolone can be increased when it is combined with Estrone.Approved
Etacrynic acidDifluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Difluocortolone.Experimental
Ethinyl EstradiolThe serum concentration of Difluocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Difluocortolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Difluocortolone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Difluocortolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Difluocortolone.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Difluocortolone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Difluocortolone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Difluocortolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Difluocortolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Difluocortolone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Difluocortolone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Difluocortolone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Difluocortolone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Difluocortolone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Difluocortolone.Experimental
FluoxymesteroneDifluocortolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Difluocortolone.Approved, Investigational
FosaprepitantThe serum concentration of Difluocortolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Difluocortolone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideDifluocortolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Difluocortolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Difluocortolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Difluocortolone is combined with GI-5005.Investigational
GLPG-0492Difluocortolone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Difluocortolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Difluocortolone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Difluocortolone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Difluocortolone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Difluocortolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Difluocortolone.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluocortolone.Approved, Investigational
HydrochlorothiazideDifluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDifluocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Difluocortolone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Difluocortolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Difluocortolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Difluocortolone.Approved, Investigational
IdelalisibThe serum concentration of Difluocortolone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Difluocortolone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Difluocortolone.Approved
IndapamideDifluocortolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Difluocortolone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Difluocortolone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difluocortolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Difluocortolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Difluocortolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Difluocortolone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Difluocortolone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Difluocortolone.Withdrawn
ItraconazoleThe serum concentration of Difluocortolone can be increased when it is combined with Itraconazole.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Difluocortolone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Difluocortolone.Experimental
KetoconazoleThe serum concentration of Difluocortolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluocortolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Difluocortolone.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Difluocortolone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Difluocortolone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difluocortolone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Difluocortolone.Experimental
LopinavirThe serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluocortolone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Difluocortolone.Approved, Investigational
LumacaftorThe serum concentration of Difluocortolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Difluocortolone.Approved, Investigational
MagaldrateThe bioavailability of Difluocortolone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium hydroxideThe bioavailability of Difluocortolone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Difluocortolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Difluocortolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluocortolone.Approved
Magnesium silicateThe bioavailability of Difluocortolone can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Difluocortolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difluocortolone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Difluocortolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Difluocortolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluocortolone.Approved
MesteroloneDifluocortolone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Difluocortolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Difluocortolone.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Difluocortolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDifluocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluocortolone.Approved, Vet Approved
MethyltestosteroneDifluocortolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Metoclopramide.Approved, Investigational
MetolazoneDifluocortolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Difluocortolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Minaprine.Approved
MitotaneThe serum concentration of Difluocortolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Difluocortolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluocortolone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Difluocortolone.Experimental
MoxestrolThe serum concentration of Difluocortolone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluocortolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Difluocortolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Difluocortolone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Difluocortolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Nalidixic Acid.Approved, Investigational
NandroloneDifluocortolone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateDifluocortolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Difluocortolone.Approved, Vet Approved
NefazodoneThe serum concentration of Difluocortolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Difluocortolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Difluocortolone.Approved, Investigational
NevirapineThe serum concentration of Difluocortolone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Difluocortolone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Difluocortolone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difluocortolone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Difluocortolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluocortolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Difluocortolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Difluocortolone.Vet Approved
OxandroloneDifluocortolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluocortolone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Oxolinic acid.Experimental
OxymetholoneDifluocortolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluocortolone.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Difluocortolone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Difluocortolone.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Difluocortolone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe serum concentration of Difluocortolone can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Difluocortolone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Difluocortolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difluocortolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Difluocortolone.Approved, Investigational
PhenytoinThe serum concentration of Difluocortolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluocortolone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pipemidic acid.Experimental
PiretanideDifluocortolone may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluocortolone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluocortolone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Difluocortolone.Experimental
Polyestradiol phosphateThe serum concentration of Difluocortolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDifluocortolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Difluocortolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Difluocortolone.Experimental, Investigational
PrimidoneThe serum concentration of Difluocortolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Difluocortolone.Experimental
PromestrieneThe serum concentration of Difluocortolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Difluocortolone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Difluocortolone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Difluocortolone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Difluocortolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pyridostigmine.Approved, Investigational
QuinestrolThe serum concentration of Difluocortolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneDifluocortolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rabies virus inactivated antigen, A.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Difluocortolone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Difluocortolone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Difluocortolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Difluocortolone can be decreased when it is combined with Rifapentine.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Difluocortolone.Approved, Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difluocortolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Difluocortolone.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Difluocortolone.Approved
SaquinavirThe serum concentration of Difluocortolone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Difluocortolone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Difluocortolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difluocortolone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Difluocortolone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Difluocortolone can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Difluocortolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Difluocortolone.Investigational
St. John's WortThe serum concentration of Difluocortolone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneDifluocortolone may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololDifluocortolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Difluocortolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difluocortolone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Difluocortolone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Difluocortolone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Difluocortolone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Difluocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Difluocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Difluocortolone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Difluocortolone.Approved, Withdrawn
TelithromycinThe serum concentration of Difluocortolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Difluocortolone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Difluocortolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Difluocortolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Difluocortolone.Approved
TestosteroneDifluocortolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateDifluocortolone may increase the fluid retaining activities of Testosterone cypionate.Approved
Testosterone enanthateDifluocortolone may increase the fluid retaining activities of Testosterone enanthate.Approved
Testosterone propionateDifluocortolone may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateDifluocortolone may increase the fluid retaining activities of Testosterone undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Difluocortolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Difluocortolone.Approved
TiboloneThe serum concentration of Difluocortolone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Difluocortolone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difluocortolone.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difluocortolone.Approved
TorasemideDifluocortolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Difluocortolone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Difluocortolone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideDifluocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Difluocortolone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluocortolone.Approved
TromethamineThe bioavailability of Difluocortolone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tubocurarine.Approved
TyrothricinThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tyrothricin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Difluocortolone.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Difluocortolone is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VoriconazoleThe serum concentration of Difluocortolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDifluocortolone may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluocortolone.Approved, Investigational
ZeranolThe serum concentration of Difluocortolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Difluocortolone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difluocortolone.Withdrawn
Food Interactions
Not Available

References

General References
  1. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P: Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. Epub 2012 Nov 5. [PubMed:23213332]
  2. Mutzel VW: [Pharmacokinetics and biotransformation of diflucortolone valerate in man (author's transl)]. Arzneimittelforschung. 1976;26(7b):1487-92. [PubMed:1036944]
  3. FDA Submission [Link]
  4. Dokteronline [Link]
  5. J-stage papers [Link]
  6. Diflucortolone monograph [Link]
  7. Medicine.ie [Link]
External Links
PubChem Compound
11954369
PubChem Substance
310265022
ChemSpider
10128664
ChEBI
135624
ChEMBL
CHEMBL509924
Wikipedia
Diflucortolone
ATC Codes
D07XC04 — DiflucortoloneD07AC06 — DiflucortoloneD07BC04 — Diflucortolone and antiseptics
MSDS
Download (114 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableAtopic Dermatitis (AD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical
CreamTopical0.1 %
OintmentTopical0.1 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220ºC'MSDS'
boiling point (°C)534ºC at 760 mmHg'MSDS'
water solubility2.030 mg/LLamparczyk H. CRC Handbook of Chromatography. (1992)
logP3.86Lamparczyk H. CRC Handbook of Chromatography. (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0446 mg/mLALOGPS
logP2.22ALOGPS
logP2.01ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.39ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity100.99 m3·mol-1ChemAxon
Polarizability40.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-hydroxy ketones / Secondary alcohols / Cyclic alcohols and derivatives / Cyclic ketones
show 6 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid / 6-halo-steroid
show 22 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Phospholipase a2 inhibitor activity
Specific Function
Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.
Gene Name
ANXA3
Uniprot ID
P12429
Uniprot Name
Annexin A3
Molecular Weight
36374.85 Da
References
  1. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P: Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. Epub 2012 Nov 5. [PubMed:23213332]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P: Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. Epub 2012 Nov 5. [PubMed:23213332]

Drug created on September 16, 2015 11:59 / Updated on May 02, 2018 01:35